Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Surface-exposed primary amines on tissue proteins, primarily the epsilon-amino groups of lysine residues and N-terminal alpha-amino groups, represent a critical class of reactive sites for chemical modification and therapeutic intervention (Hermanson, 2013). These amines are typically solvent-accessible and possess a lone pair of electrons that makes them potent nucleophiles at physiological pH. In the field of bioprosthetics, these groups are the primary targets for cross-linking agents like glutaraldehyde, which stabilize the extracellular matrix of animal-derived tissues to enhance durability and minimize immunogenicity upon implantation (Migneault et al., 2004; Jayakrishnan & Jameela, 1996). Beyond structural stabilization, these amines are the focal point for bioconjugation strategies, including the attachment of polyethylene glycol (PEGylation) or cytotoxic payloads in antibody-drug conjugates (ADCs) via N-hydroxysuccinimide (NHS) ester chemistry (Hermanson, 2013). Pathologically, the non-enzymatic glycation of these amines by reducing sugars leads to the formation of advanced glycation end-products (AGEs), which are key drivers of vascular stiffening and organ damage in chronic conditions such as diabetes and aging (Singh et al., 2001; Schmidt et al., 1994).
Covalent modification through nucleophilic attack by the primary amine on electrophilic centers (e.g., aldehydes, NHS esters) to form stable linkages such as Schiff bases or amide bonds (Hermanson, 2013; Migneault et al., 2004).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Surface-exposed primary amines on tissue proteins.